N@N

HXL, ISIS, MRX, TRLG, CNC, DVR Expected To Be Higher Leading Up To Next Earnings Releases

^{Published on 2009-07-23 11:38:56, Last Modified on 2010-12-22 14:35:50 - WOPRAI}
 

July 24, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and July/August earnings reports. Hexcel Corp (NYSE: HXL0, Isis Pharmaceuticals (NASDAQ: ISIS), Medicis Pharmaceutical (NYSE: MRX), True Religion Apparel (NASDAQ: TRLG), Centene Corp (NYSE: CNC) and Cal Dive International (NYSE: DVR) are all expected to be higher leading up to their next earnings release. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act before its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go higher leading up to their next earnings release:

Symbol Company # of Reports Quarter Release Date

HXL Hexcel Corporation 12 quarters Q2 7/27/2009

ISIS Isis Pharmaceuticals August earnings Q2 8/6/2009

MRX Medicis Pharmaceutical August earnings Q2 8/4/2009

TRLG True Religion Apparel 12 quarters Q2 8/4/2009

CNC Centene Corp. July earnings Q2 7/28/2009

DVR Cal Dive International 12 quarters Q2 7/29/2009

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event. because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Hexcel Corporation (NSYE: HXL), together with its subsidiaries, engages in the development, manufacture, and marketing of composites for use in the commercial aerospace, space and defense, and industrial applications. It operates in two segments, Composite Materials and Engineered Products. The Composite Materials segment manufactures and markets carbon fibers, fabrics and specialty reinforcements, prepregs, structural adhesives, honeycomb, composite panels, molding compounds, polyurethane systems, gel coats, and laminates. The Engineered Products segment manufactures and markets composite structures and precision machined honeycomb parts, such as aerodynamic fairings, wing panels, rotor blades, and other specific aircraft components. The companya�s products are used in various end applications, including commercial and military aircraft, space launch vehicles and satellites, wind turbine blades, automotive, bikes, skis, and various other industrial applications. Hexcel Corporation sells and markets its products directly, as well as through independent distributors and manufacturer representatives. It sells its products in the United States, France, Austria, the United Kingdom, and internationally. The company was founded in 1946 and is based in Stamford, Connecticut.

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) engages in RNA-based drug discovery and development for its product pipeline and for its partners. It primarily offers Vitravene, an antisense drug to treat cytomegalovirus retinitis in AIDS patients. The company has approximately 19 drugs in development, including Mipomersen (ISIS 301012) for familial hypercholesterolemia patients; ISIS-CRPRx, an antisense drug; BMS-PCSK9Rx that targets proprotein convertase subtilisin/kexin type 9; OMJP-GCGR, a glucagon receptor; OMJP-GCCR, a glucocorticoid receptor; and ISIS-SGLT2Rx, which targets sodiuma"glucose co-transporter type 2. Its cancer products under development include OGX-011, a secreted protein that acts as a cell-survival protein; OGX-427, a drug targeting heat shock protein 27; LY2181308 that targets survivin; and LY2275796 for eukaryotic initiation factor-4E. Isis Pharmaceuticals also develops ISIS-SOD1Rx to treat amyotrophic lateral sclerosis; ACHN-490 for the treatment of multi-drug resistant gram-negative bacterial infections; AIR645 to treat respiratory conditions; Alicaforsen and ATL/TV1102 for the treatment of inflammatory disorders; ATL1103, a receptor that reduces the level of circulating insulin-like growth factor-1; EXC001 to treat fibrotic diseases; and iCo-007 for the treatment of various eye diseases. The company also focuses on the development and commercialization of microRNA therapeutics. It has strategic alliances/collaboration/licensing agreements with Genzyme Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Achaogen, Inc.; Altair Therapeutics Inc.; Antisense Therapeutics Limited; Atlantic Pharmaceuticals Limited; Excaliard Pharmaceuticals, Inc.; iCo Therapeutics Inc.; OncoGenex Technologies Inc.; Novosom AG; Archemix Corp.; Ercole Biotech, Inc.; Santaris Pharma A/S; and Alnylam Pharmaceuticals, Inc. The company was founded in 1989 and is based in Carlsbad, California.

Medicis Pharmaceutical Corporation (NYSE: MRX) operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions. The companya�s products address various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. Its products include DYNACIN for the treatment of acne and acne-related dermatological conditions; PLEXION, a cleanser product; SOLODYN for the treatment of inflammatory lesions; TRIAZ, a benzoyl peroxide pad for the topical treatment of acne vulgaris; and ZIANA, a gel used on the skin for treatment of acne in patients 12 and older. The company also offers LOPROX, a shampoo; PERLANE and RESTYLANE for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds; and VANOS, a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. In addition, Medicis Pharmaceutical provides non-dermatological products, including AMMONUL for treating hepatic encephalopathies; and BUPHENYL for the treatment of urea cycle disorder. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has a joint development agreement with IMPAX Laboratories, Inc. to develop of five strategic dermatology product opportunities, including an advanced-form SOLODYN product; a strategic alliance with AAIPharma, Inc. for the development, commercialization, and license of a key dermatologic product, SOLODYN; and a strategic collaboration with Hyperion Therapeutics, Inc. for the research and development of a compound referred to as GT4P for the treatment of urea cycle disorder and hepatic encephalopathies. The company was founded in 1987 and is headquartered in Scottsdale, Arizona.

True Religion Apparel, Inc. (NASDAQ: TRLG) engages in the design, development, manufacture, marketing, distribution, and sale of apparel in North and South America, Asia, Africa, Europe, and Australia. It offers fashion jeans and related sportswear apparel. The companya�s products include denim jeans and jackets; corduroy pants and jackets; cotton, twill, linen, and velvet pants and jackets; fleece sweat suits and hooded sweatshirts; skirts; knit shirts; t-shirts; shorts; and sportswear for men, women, and children under True Religion Brand Jeans brand name. True Religion sells its products through stores, specialty retailers, boutiques, distributors, and sales agents, as well as licenses its various trademarks to third parties. As of December 31, 2008, the company operated 42 branded retail stores. True Religion is headquartered in Vernon, California.

Centene Corporation (NYSE: CNC) operates as a multiline healthcare company in the United States. It operates through two segments, Medicaid Managed Care and Specialty Services. The Medicaid Managed Care segment provides medicaid and medicaid-related health plan coverage to individuals through government subsidized programs, including medicaid, the state childrena�s health insurance program, and supplemental security income. These programs provide primary and specialty physician care, inpatient and outpatient hospital care, transportation assistance, emergency and urgent care, vision care, prenatal care, dental care, laboratory and x-ray services, home health and durable medical equipment, immunizations, prescriptions and over-the-counter drugs, and behavioral health and substance abuse services. The Specialty Services segment offers specialty services, such as behavioral health, disease management, long-term care programs, managed vision, nurse triage, pharmacy benefits management, and treatment compliance to state programs, healthcare organizations, employer groups, and other commercial organizations. The company also provides education and outreach programs to inform and assist members in accessing healthcare services. Centene offers its services through primary and specialty care physicians, hospitals, and ancillary providers. The company was founded in 1984 and is headquartered in St. Louis, Missouri.

Cal Dive International, Inc. (NYSE: DVR), a marine contracting company, provides marine construction, diving, and offshore services to offshore oil and natural gas industry. The company offers manned diving, pipelay and pipe burial, platform installation, saturation, and platform salvage services, as well as construction, inspection, maintenance, and repair and decommissioning of offshore production and pipeline infrastructure. It primarily operates in the Gulf of Mexico Outer Continental Shelf, the northeastern U.S., Latin America, southeast Asia, Australia, the Middle East, India, and the Mediterranean. Cal Dive International provides its services to oil and natural gas producers, pipeline transmission companies, and offshore engineering and construction firms. As of December 31, 2008, it owned and operated a fleet of 31 vessels, including 21 surface and saturation diving support vessels, 6 pipelay/pipebury barges, 1 pipebury barge, 1 combination derrick/pipelay barge, and 2 derrick barges. The company was founded in 1975 and is headquartered in Houston, Texas. Cal Dive International, Inc. is a subsidiary of Helix Energy Solutions Group, Inc.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

One example from the SqueezeTrigger database is approximately 2.5 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering!

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641